# Noom's GLP-1 Program Pairs Medication with Behavioral Support
Noom Med has launched a GLP-1 prescription program that combines weight loss medications with the company's existing behavioral coaching platform. The service delivers personalized pharmaceutical support alongside Noom's established psychology-based approach to habit change.
GLP-1 receptor agonists like semaglutide and tirzepatide suppress appetite and improve blood sugar control. These drugs have shown strong results in clinical trials, but medication alone addresses only part of the weight loss equation. Noom's model bridges that gap by pairing prescriptions with daily coaching, food tracking, and cognitive behavioral therapy techniques.
The program operates through Noom's existing app infrastructure. Users receive medical consultations to determine eligibility, then get ongoing support from the coaching team while taking their prescribed medication. This integrated approach attempts to solve a common problem with weight loss drugs. People often regain weight once they stop taking them because they haven't developed the behavioral habits needed to maintain results.
Noom's behavioral framework focuses on understanding eating patterns rather than restrictive dieting. Coaches help users identify triggers, adjust their relationship with food, and build sustainable routines. When combined with a medication that reduces hunger signals, this pairing theoretically creates better long-term outcomes than either approach alone.
The accessibility question remains open. GLP-1 medications carry significant costs, though insurance sometimes covers them for diabetes or obesity. Noom's platform subscription adds another expense. The combination may price out many people seeking weight loss support.
The clinical evidence supporting behavioral therapy alongside weight loss medications exists. Studies show that people who receive psychological support with pharmaceutical treatment maintain better results than those using medication exclusively. Noom's move formalizes what research has demonstrated for years. whether the business model remains affordable for average consumers remains to be seen.